Literature DB >> 9532519

Stepped care for hypertension: are the assumptions valid?

J J Caro1.   

Abstract

OBJECTIVE: To examine whether the choice of initial antihypertensive medication is associated with patient withdrawal from therapy among a large cohort of newly diagnosed hypertensive individuals receiving medical care in actual practice.
DESIGN: The records of the outpatient prescription drug plan of Saskatchewan, Canada, were searched for individuals with a diagnosis of essential hypertension who were receiving at least one antihypertensive drug between January 1989 and December 1994. Persistence was defined, and records were classified by class of initial antihypertensive agent prescribed.
SUBJECTS: In all, the records of over 79,000 individuals with a diagnosis of hypertension and an antihypertensive drug prescribed between 1990 and 1994 were evaluated. Persistence with therapy was considered in a subset of newly diagnosed patients, observed for at least 6 months, and receiving an initial prescription from one of four major categories of antihypertensive agents.
RESULTS: Among newly diagnosed patients, diuretics and angiotensin converting enzyme (ACE) inhibitors were the most common initial medication. ACE inhibitors were associated with the highest persistence rates after 1 year of follow-up (83%), followed by calcium antagonists (81%), diuretics (78%) and beta-blockers (74%) (P < 0.001). These results were unchanged in a Cox proportional hazards model which controlled for confounding by age, sex and proxy measures for prior health status.
CONCLUSIONS: A significant proportion of newly diagnosed patients withdraw from therapy within the first year, and this withdrawal seems to be related to the choice of initial antihypertensive agent. These results suggest that recommendations for using stepped care in hypertension management may not be optimal if the initial agent prescribed is associated with decreased levels of persistence with therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9532519

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  3 in total

Review 1.  Adverse events, compliance, and changes in therapy.

Authors:  R Düsing
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

Review 2.  Compliance and persistence with newer antihypertensive agents.

Authors:  William C Gerth
Journal:  Curr Hypertens Rep       Date:  2002-12       Impact factor: 5.369

Review 3.  Pharmacoeconomic burden of undertreating hypertension.

Authors:  Luca Degli Esposti; Giorgia Valpiani
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.